<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ru">
	<id>https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=DTL</id>
	<title>DTL - История изменений</title>
	<link rel="self" type="application/atom+xml" href="https://transhumanist.ru/index.php?action=history&amp;feed=atom&amp;title=DTL"/>
	<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=DTL&amp;action=history"/>
	<updated>2026-06-15T01:26:58Z</updated>
	<subtitle>История изменений этой страницы в вики</subtitle>
	<generator>MediaWiki 1.43.6</generator>
	<entry>
		<id>https://transhumanist.ru/index.php?title=DTL&amp;diff=6424&amp;oldid=prev</id>
		<title>OdysseusBot: Новая страница: «Denticleless protein homolog (DDB1- and CUL4-associated factor 2) (Lethal(2) denticleless protein homolog) (Retinoic acid-regulated nuclear matrix-associated prot...»</title>
		<link rel="alternate" type="text/html" href="https://transhumanist.ru/index.php?title=DTL&amp;diff=6424&amp;oldid=prev"/>
		<updated>2021-05-12T15:29:41Z</updated>

		<summary type="html">&lt;p&gt;Новая страница: «Denticleless protein homolog (DDB1- and CUL4-associated factor 2) (Lethal(2) denticleless protein homolog) (Retinoic acid-regulated nuclear matrix-associated prot...»&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Новая страница&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Denticleless protein homolog (DDB1- and CUL4-associated factor 2) (Lethal(2) denticleless protein homolog) (Retinoic acid-regulated nuclear matrix-associated protein) [CDT2] [CDW1] [DCAF2] [L2DTL] [RAMP]&lt;br /&gt;
&lt;br /&gt;
==Publications==&lt;br /&gt;
&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=Targeting [[DTL]] induces cell cycle arrest and senescence and suppresses cell growth and colony formation through [[TPX2]] inhibition in human hepatocellular carcinoma cells.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/29606879&lt;br /&gt;
|abstract=Hepatocellular carcinoma (HCC) has an increasing incidence and high mortality. Surgical operation is not a comprehensive strategy for liver cancer. Moreover, tolerating systemic chemotherapy is difficult for patients with HCC because hepatic function is often impaired due to underlying cirrhosis. Therefore, a comprehensive strategy for cancer treatment should be developed. [[DTL]] (Cdc10-dependent transcript 2) is a critical regulator of cell cycle progression and genomic stability. In our previous study, the upregulation of [[DTL]] expression in aggressive HCC correlated positively with tumor grade and poor patient survival. We hypothesize that targeting [[DTL]] may provide a novel therapeutic strategy for liver cancer. [[DTL]] small interference RNAs were used to knock down [[DTL]] protein expression. A clonogenic assay, immunostaining, double thymidine block, imaging flow cytometry analysis, and a tumor spheroid formation assay were used to analyze the role of [[DTL]] in tumor cell growth, cell cycle progression, micronucleation, ploidy, and tumorigenicity. Our results demonstrated that targeting [[DTL]] reduced cell cycle regulators and chromosome segregation genes, resulting in increased cell micronucleation. [[DTL]] depletion inhibited liver cancer cell growth, increased senescence, and reduced tumorigenesis. [[DTL]] depletion resulted in the disruption of the mitotic proteins cyclin B, [[CDK1]], securin, seprase, Aurora A, and Aurora B as well as the upregulation of the cell cycle arrest gene [i]p21[/i]. A rescue assay indicated that [[DTL]] should be targeted through [[TPX2]] downregulation for cancer cell growth inhibition. Moreover, [[DTL]] silencing inhibited the growth of patient-derived primary cultured HCC cells. Our study results indicate that [[DTL]] is a potential novel target gene for treating liver cancer through liver cancer cell senescence induction. Furthermore, our results provide insights into molecular mechanisms for targeting [[DTL]] in liver cancer cells. The results also indicate several other starting points for future preclinical and clinical studies on liver cancer treatment.&lt;br /&gt;
&lt;br /&gt;
|keywords=* DTL&lt;br /&gt;
* TPX2&lt;br /&gt;
* cell cycle&lt;br /&gt;
* hepatocellular carcinoma&lt;br /&gt;
* senescence&lt;br /&gt;
|full-text-url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5868578&lt;br /&gt;
}}&lt;br /&gt;
{{medline-entry&lt;br /&gt;
|title=Expression of aquaporins-1 and -2 during nephrogenesis and in autosomal dominant polycystic kidney disease.&lt;br /&gt;
|pubmed-url=https://pubmed.ncbi.nlm.nih.gov/8760258&lt;br /&gt;
|abstract=Aquaporin-1 ([[AQP1]]), located in proximal tubules (PT) and descending thin limbs of Henle ([[DTL]]), and aquaporin-2 ([[AQP2]]), located in collecting ducts (CD), are channels involved in water transport across renal tubule epithelia. Using antibodies against [[AQP1]] and [[AQP2]], we here show expression of [[AQP1]] and [[AQP2]] in normal human developing and adult kidneys and in autosomal dominant polycystic kidney disease (ADPKD). Unlike in rats, [[AQP1]] and [[AQP2]] are expressed early during human nephrogenesis (12-wk gestation). [[AQP1]] was first seen in developing PT epithelia, predominantly in apical cell membranes, and, at 15 wk, was also detected in [[DTL]]. [[AQP2]] was seen in apical cell membranes of the branching ureteric bud and CD system from 12 wk and throughout development. In adult normal kidneys, [[AQP1]] was localized to apical and basolateral membrane domains of PT and [[DTL]], whereas [[AQP2]] was restricted to principal cells of CD. This distribution of [[AQP1]] and [[AQP2]] was also seen in early stage ADPKD, except that [[AQP1]] was mostly located in the apical membrane region of expanded PT. In end-stage ADPKD, two-thirds of the cysts expressed either [[AQP1]] or [[AQP2]], but these two water channels were never colocalized in the same cyst. Western blot analysis showed maximal expression of [[AQP1]] and [[AQP2]] in normal adult kidneys, lower levels in fetal kidneys, and decreases associated with degree of cystic progression in ADPKD. These data 1) demonstrate specific, mutually exclusive localization of [[AQP1]] and [[AQP2]] in human fetal and adult kidneys; 2) show that both channels are expressed early during nephrogenesis; and 3) show that the mutual exclusivity of localization is maintained even into end-stage ADPKD.&lt;br /&gt;
|mesh-terms=* Aging&lt;br /&gt;
* Amino Acid Sequence&lt;br /&gt;
* Animals&lt;br /&gt;
* Animals, Newborn&lt;br /&gt;
* Aquaporin 1&lt;br /&gt;
* Aquaporin 2&lt;br /&gt;
* Aquaporin 6&lt;br /&gt;
* Aquaporins&lt;br /&gt;
* Blood Group Antigens&lt;br /&gt;
* Blotting, Western&lt;br /&gt;
* Embryonic and Fetal Development&lt;br /&gt;
* Humans&lt;br /&gt;
* Immunohistochemistry&lt;br /&gt;
* Ion Channels&lt;br /&gt;
* Kidney&lt;br /&gt;
* Molecular Sequence Data&lt;br /&gt;
* Polycystic Kidney, Autosomal Dominant&lt;br /&gt;
* Rats&lt;br /&gt;
* Reference Values&lt;br /&gt;
* Staining and Labeling&lt;br /&gt;
&lt;br /&gt;
|full-text-url=https://sci-hub.do/10.1152/ajprenal.1996.271.1.F169&lt;br /&gt;
}}&lt;/div&gt;</summary>
		<author><name>OdysseusBot</name></author>
	</entry>
</feed>